[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 735
Citations 0
September 2017

Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels

Author Affiliations
  • 1Heart and Vascular Center, Department of Medicine/Cardiology, School of Medicine, University of North Carolina, Chapel Hill
JAMA Cardiol. 2017;2(9):946-947. doi:10.1001/jamacardio.2017.2290

The 2013 American College of Cardiology and American Heart Association (ACC/AHA) Guidelines on Treatment to Lower Blood Cholesterol1 recommend high-intensity statin therapy for patients with atherosclerotic cardiovascular disease (ASCVD), with a provision to use nonstatin therapies with proven clinical outcome benefit when the anticipated therapeutic response of at least 50% lowering of low-density lipoprotein cholesterol (LDL-C) level is not seen with high-intensity statin therapy, and further suggest an LDL-C level of at least 100 mg/dL with high-intensity therapy as criteria for adding nonstatin therapy with established clinical benefit. The 2016 ACC Expert Consensus Decision Pathway2 supports this approach.